Drug Profile
Research programme: chemokine receptor antagonists - Biotherapix
Alternative Names: Btx 501; Btx 502; DiakinesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Biotherapix
- Class
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Spain
- 30 Aug 2007 Preclinical trials in Inflammation in Spain (unspecified route)